secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001104659-25-101817
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports VS-7375 clears first two doses with tumor reduction in 4/5 evaluable patients
--------------------------------------------------------------------------------

- No DLTs at 400 mg QD and 600 mg QD; no nausea/vomiting/diarrhea > Grade 1.
- 4 of 5 efficacy-evaluable patients had tumor reduction and remain on treatment.
- Enrollment started for VS-7375 + cetuximab combo cohort in advanced solid tumors.
- Interim safety/efficacy update expected in first half 2026.
- Monotherapy dose escalation continues to 900 mg QD to select recommended Phase 2 dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/0001104659-25-101817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/tm2529362d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-101817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer